Dr. Larson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5841 S Maryland Ave
Chicago, IL 60637Phone+1 888-824-0200Fax+1 773-702-3002
Summary
- Dr. Richard Larson is a hematologist-oncologist in Chicago, IL, and is affiliated with University of Chicago Medical Center. He received his medical degree from Stanford University School of Medicine and has been in practice >40 years. He specializes in hematologic oncology and is experienced in acute and chronic leukemia, chemotherapy, hematologic oncology, marrow transplantation and cellular therapy, and aplastic anemia.
Education & Training
University of ChicagoFellowship, Hematology and Medical Oncology, 1980 - 1983- University of ChicagoResidency, Internal Medicine, 1977 - 1980
Stanford University School of MedicineClass of 1977
Certifications & Licensure
IL State Medical License 1978 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Super Doctor SuperDoctors.com
Clinical Trials
- Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML Start of enrollment: 2009 Oct 01
- Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation) Start of enrollment: 2009 Mar 01
- A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation Start of enrollment: 2013 Aug 12
- Join now to see all
Publications & Presentations
PubMed
- 66 citationsEtiology and Management of Therapy-Related Myeloid LeukemiaRichard A. Larson
Hematology. American Society of Hematology. Education Program. 2007-01-01 - 795 citationsEuropean LeukemiaNet 2020 recommendations for treating chronic myeloid leukemiaAndreas Hochhaus, Michele Baccarani, Richard T. Silver, Charles A. Schiffer, Jane F. Apperley
Leukemia. 2020-04-01 - 280 citationsPrognostic Factors and Outcome of Core Binding Factor Acute Myeloid Leukemia Patients With t(8;21) Differ From Those of Patients With inv(16): A Cancer and Leukemia Gr...Guido Marcucci, Krzysztof Mrózek, Amy S. Ruppert, Kati Maharry, Jonathan E. Kolitz
Journal of Clinical Oncology. 2005-08-20
Abstracts/Posters
- Outcomes of IDH-Mutated Advanced Phase Ph-Negative Myeloproliferative Neoplasms Treated with IDH InhibitorsRichard A. Larson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Ibrutinib and Venetoclax Target Distinct Subpopulation of CLL Cells: Rationale for Drug Combination and Implication of Minimal Residual Disease EradicationRichard A. Larson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDSRichard A. Larson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- ABL Tyrosine Kinase Inhibitors (TKIs) Are Associated with Increased Rho-Associated Kinase (ROCK) Activity That May Contribute to Vascular Toxicity in Patients with Chr...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Event-Free Survival As a Surrogate Endpoint for Overall Survival in Previously Untreated Acute Myeloid Leukemia: An Individual Patient-Level Analysis of Multiple Rando...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete R...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Authored Content
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 MutationJune 2017
Press Mentions
1st Patient Dosed with Cellectis’ Allogeneic UCART22 in Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaDecember 2nd, 2019
Uchicago Medicine Oncologist to Receive 2019 Henry M. Stratton Medal for Hematology ResearchAugust 13th, 2019
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
